Oncozenge AB (ONCOZ) - Total Assets
Based on the latest financial reports, Oncozenge AB (ONCOZ) holds total assets worth Skr15.34 Million SEK (≈ $1.65 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Oncozenge AB investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Oncozenge AB - Total Assets Trend (2020–2025)
This chart illustrates how Oncozenge AB's total assets have evolved over time, based on quarterly financial data. Check Oncozenge AB (ONCOZ) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Oncozenge AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Oncozenge AB's total assets of Skr15.34 Million consist of 55.3% current assets and 44.7% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 24.2% |
| Accounts Receivable | Skr4.77 Million | 31.1% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr6.85 Million | 44.7% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Oncozenge AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ONCOZ stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oncozenge AB's current assets represent 55.3% of total assets in 2025, an increase from 40.5% in 2020.
- Cash Position: Cash and equivalents constituted 24.2% of total assets in 2025, down from 26.1% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 44.0% of total assets, a decrease from 57.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 44.7% of total assets.
Oncozenge AB Competitors by Total Assets
Key competitors of Oncozenge AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Oncozenge AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.01 | 3.09 | 5.59 |
| Quick Ratio | 1.01 | 3.09 | 6.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr63.00K | Skr3.10 Million | Skr58.99 Million |
Oncozenge AB - Advanced Valuation Insights
This section examines the relationship between Oncozenge AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.59 |
| Latest Market Cap to Assets Ratio | 0.74 |
| Asset Growth Rate (YoY) | 34.1% |
| Total Assets | Skr15.34 Million |
| Market Capitalization | $11.41 Million USD |
Valuation Analysis
Below Book Valuation: The market values Oncozenge AB's assets below their book value (0.74x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Oncozenge AB's assets grew by 34.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Oncozenge AB (2020–2025)
The table below shows the annual total assets of Oncozenge AB from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr15.34 Million ≈ $1.65 Million |
+34.14% |
| 2024-12-31 | Skr11.43 Million ≈ $1.23 Million |
-43.79% |
| 2023-12-31 | Skr20.34 Million ≈ $2.19 Million |
-44.87% |
| 2022-12-31 | Skr36.89 Million ≈ $3.97 Million |
-56.71% |
| 2021-12-31 | Skr85.23 Million ≈ $9.17 Million |
+122.55% |
| 2020-12-31 | Skr38.30 Million ≈ $4.12 Million |
-- |
About Oncozenge AB
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.